New Alzheimer’s guidance

With new evidence showing that the biological changes associated with Alzheimer’s disease start earlier than expected, the European Medicines Agency has revised its guideline for companies developing drugs for the disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom